What do we already know about this topic?

• Erenumab and galcanezumab are monoclonal antibodies which bind to the calcitonin gene-related peptide (CGRP) receptor and CGRP molecule, respectively, and have been approved for the preventive treatment of migraine.
• Real-world data on patients being switched between erenumab and galcanezumab is limited.

How was this study conducted?

• A retrospective chart review of patients with migraine (N=100) who were who switched from erenumab to galcanezumab between May 1, 2018, and October 1, 2019, at a single headache center.
• Demographic information, length of treatment, patient-reported efficacy, side effects, and reasons for discontinuation were collected and analyzed.